Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17942351 | 1.00 | KDM4E (0.50) | KDM4EPKMGPR119SMN1; SMN2GAA | |
| SCHEMBL1474954 | 0.85 | KDM4E (0.53) | KDM4EPKMGPR119SMN1; SMN2GAA | |
| SCHEMBL25571744 | 0.80 | GPR119 (0.49) | KDM4EPKMGPR119STSMAPT | |
| SCHEMBL4248138 | 0.80 | KDM4E (0.60) | KDM4EPKMGPR119SMN1; SMN2GAA | |
| SCHEMBL30833439 | 0.80 | KDM1A (0.44) | GPR119MAPTMEN1KMT2A | |
| SCHEMBL17942505 | 0.80 | KDM4E (0.41) | KDM4EPKMGPR119SMN1; SMN2GAA | |
| SCHEMBL17948970 | 0.78 | KDM4E (0.50) | KDM4EPKMGPR119STSTGFBR1 | |
| SCHEMBL29529409 | 0.78 | KDM4E (0.50) | KDM4EPKMGPR119STSTGFBR1 | |
| SCHEMBL17948871 | 0.77 | POLB (0.56) | KDM4EPKMGPR119SMN1; SMN2GAA | |
| SCHEMBL25571737 | 0.77 | KDM4E (0.49) | KDM4EPKMGPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MYOKARDIA INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | KDM4E 45/4885PKM 821/4885GPR119 3908/4885 |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | KDM4E 45/4885PKM 821/4885GPR119 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.